Comparing Moolec Science (MLEC) & The Competition

Moolec Science (NASDAQ:MLEC) is one of 500 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Moolec Science to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for Moolec Science and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	1012	2917	7310	145	2.58

Moolec Science presently has a consensus target price of $6.00, suggesting a potential upside of 574.16%. As a group, “Biotechnology” companies have a potential upside of 23.22%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities analysts clearly believe Moolec Science is more favorable than its peers.

Earnings and Valuation

This table compares Moolec Science and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.45
Moolec Science Competitors	$1.56 billion	$45.42 million	121.33

Moolec Science’s peers have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Moolec Science has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 1.22, suggesting that their average stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,106.44%	-101.85%	-27.70%

Institutional & Insider Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 33.4% of shares of all “Biotechnology” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by insiders. Comparatively, 19.9% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Moolec Science peers beat Moolec Science on 8 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.